# Maven Bio **Source:** https://geo.sig.ai/brands/maven-bio **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** mavenbio.io **Last Updated:** 2026-04-14 ## Summary Boston biopharma AI platform automating competitive landscape, regulatory intelligence, and clinical research for DayOne and ZS Associates; YC $3.1M Pags/Splash seed competing with Citeline and Evaluate for AI-powered pharma knowledge work. ## Company Overview Maven Bio is a Boston, Massachusetts-based AI platform for biopharma knowledge work — backed by Y Combinator with $3.1 million in seed funding led by Pags Group, Splash Capital, and NVO Group with YC participation, following a $500,000 pre-seed from YC in September 2023 — providing biopharma companies, consultancies, and investors with domain-specific AI modules built on curated biopharma industry data that automate the research, analysis, and synthesis tasks that pharmaceutical knowledge workers perform manually. Founded in 2023 by Michael Brady and Arjun Murthy and operating with an 8-person team in Boston, Maven Bio serves customers including DayOne and ZS Associates (the global biopharma consulting firm) with a platform that converts biopharma questions into decisions faster through AI-powered access to curated drug development, clinical, and regulatory knowledge. Maven Bio's product suite addresses the knowledge bottleneck in pharmaceutical decision-making: biopharma professionals (drug developers, market access teams, medical affairs, investors evaluating deals) spend significant time researching the competitive landscape (finding all drugs in development for a target indication), regulatory history (understanding FDA precedents for a drug class), payer coverage patterns (identifying how commercial payers currently reimburse similar products), and clinical evidence (synthesizing trial design and outcomes across therapeutic area literature). Each of these research tasks currently requires hours of database querying, literature review, and manual synthesis that Maven's domain-specific AI modules — Maven Atlas (competitive landscape mapping), Maven Compass (regulatory intelligence), Maven Workflows (automated research workflows), and Maven Assistant (conversational research interface) — execute in minutes using curated, validated biopharma data sources rather than the hallucination-prone general web searches that generic LLMs use for specialized pharmaceutical questions. In 2025, Maven Bio competes in the biopharma AI, pharmaceutical intelligence, and life sciences knowledge management market with Citeline (formerly Informa Pharma Intelligence, clinical trial databases), Evaluate (pharma market intelligence, acquired by Norstella), and Cradle (AI for drug design, $24M raised) for biopharma team and investor AI-powered pharmaceutical intelligence adoption. The biopharma domain-specific AI market has differentiated from general LLM access by offering curated, validated pharmaceutical data sets that reduce the hallucination risk inherent in asking general AI assistants about drug mechanisms, clinical trial designs, or regulatory precedents — domains where inaccuracy creates liability and decision risk. ZS Associates' customer status (ZS is one of the world's leading pharmaceutical consulting firms) validates Maven Bio's accuracy and relevance for professional biopharma decision support. Y Combinator backing connects Maven with the biotech and healthcare AI investor community. The 2025 strategy focuses on growing the enterprise biopharma consulting and pharma company subscriptions, building the deal analysis module for pharmaceutical BD and licensing evaluation, and expanding the real-world evidence integration for payer evidence and outcomes data. ## Frequently Asked Questions ### What is Maven Bio? Maven Bio is a biopharma AI company founded in 2023 that builds an AI platform for BioPharma knowledge work. The company transforms biopharma decision-making from question to decision using domain-specific AI and curated industry data. ### What products and services does Maven Bio offer? Maven Bio offers a BioPharma AI platform with four main modules: Maven Workflows, Atlas, Compass, and Assistant. These tools are designed to transform BioPharma knowledge work and reduce manual work in the industry. ### Who are Maven Bio's target customers? Maven Bio serves biopharma consultancies, investors, and corporate teams. Current customers include DayOne and ZS Associates, along with other biopharma consultancies and public biopharma companies. ### When was Maven Bio founded? Maven Bio was founded in 2023 by Michael Brady and Arjun Murthy. The company participated in Y Combinator's S23 batch. ### Where is Maven Bio located? Maven Bio is based in Boston, Massachusetts, United States. ### How much funding has Maven Bio raised? Maven Bio has raised a total of $3.6M, including a $3.1M seed round led by Pags Group, Splash Capital, NVO Group, and Y Combinator, plus a $500K pre-seed round from Y Combinator in September 2023. ### How large is Maven Bio's team? Maven Bio currently has an 8-person team based in Boston. ### What technology approach does Maven Bio use? Maven Bio uses domain-specific AI combined with curated industry data specifically tailored for the biopharma sector. This approach enables the platform to handle specialized BioPharma knowledge work more effectively. ### Who founded Maven Bio? Maven Bio was founded by Michael Brady and Arjun Murthy in 2023. ### What are Maven Bio's recent achievements? Maven Bio was accepted into Y Combinator's S23 batch and successfully raised $3.6M in funding. The company has secured notable customers including DayOne and ZS Associates within its first year of operation. ## Tags healthtech, b2b, ai-powered, north-america --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*